


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Pimavanserin. [Updated 2022 Nov 30]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Pimavanserin

Revised: November 30, 2022.

CASRN: 706779-91-1



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of pimavanserin during breastfeeding. If pimavanserin is required by the mother, it is not a reason to discontinue breastfeeding. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Haloperidol, Olanzapine, Quetiapine, Risperidone

Substance Identification

Substance Name

Pimavanserin

CAS Registry Number

706779-91-1

Drug Class

Breast Feeding Lactation Milk, Human Antiparkinson Agents Antipsychotic Agents Serotonin 5-HT2 Receptor Antagonists